Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,721 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07833202 | A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | not yet recruiting | Phase 3 | 416 | Shanghai Jeyou Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07816380 | A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 216 | Guangzhou JOYO Pharma Co., LtdINDUSTRY |
| 0 |
| Sep 22, 2026 |
| clinicaltrials |
| NCT07831863 | A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy | not yet recruiting | Phase 3 | 600 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07822542 | A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 448 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07802821 | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 556 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07796100 | A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 530 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 0 | Aug 31, 2026 | clinicaltrials |
| NCT07739186 | A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) | not yet recruiting | Phase 2 / Phase 3 | 120 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07680790 | Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) | not yet recruiting | Phase 3 | 850 | Bristol-Myers SquibbINDUSTRY | 16 | Aug 24, 2026 | clinicaltrials |
| NCT07718737 | Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy | not yet recruiting | Phase 2 / Phase 3 | 512 | Multitude Therapeutics Inc.INDUSTRY | 2 | Aug 10, 2026 | clinicaltrials |
| NCT07754123 | Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC | not yet recruiting | Phase 3 | 206 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Aug 10, 2026 | clinicaltrials |
| NCT07728955 | A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy(SCLC) | not yet recruiting | Phase 3 | 64 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT07662811 | SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 396 | Shanghai Chest HospitalOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07672223 | A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 3 | 570 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jun 26, 2026 | clinicaltrials |
| NCT07633873 | SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC(SYNSTAR 04) | not yet recruiting | Phase 3 | 500 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07636226 | QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07637513 | Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer(PrE0512) | not yet recruiting | Phase 3 | 430 | PrECOG, LLC.OTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07608159 | Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. | not yet recruiting | Phase 3 | 201 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | May 29, 2026 | clinicaltrials |
| NCT07376382 | A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC(SYNSTAR-02) | not yet recruiting | Phase 3 | 680 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | May 13, 2026 | clinicaltrials |
| NCT07560358 | Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 204 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07477808 | Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 116 | Hunan Province Tumor HospitalOTHER | 0 | Mar 23, 2026 | clinicaltrials |
| NCT07464327 | A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations | not yet recruiting | Phase 3 | 450 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Mar 11, 2026 | clinicaltrials |
| NCT07442565 | SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ(SYNSTAR03) | not yet recruiting | Phase 3 | 506 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 4, 2026 | clinicaltrials |
| NCT07383116 | Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 500 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07361484 | Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) | not yet recruiting | Phase 3 | 442 | BeyondSpring Pharmaceuticals Inc.INDUSTRY | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07289646 | Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy(Pegasus 2) | not yet recruiting | Phase 3 | 418 | University Hospital, BrestOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07242274 | Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC | not yet recruiting | Phase 3 | 472 | JemincareINDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07197853 | Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial(HAMSTER) | not yet recruiting | Phase 3 | 180 | Xin YeOTHER | 0 | Sep 29, 2025 | clinicaltrials |
| NCT07154368 | JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs. | not yet recruiting | Phase 3 | 207 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 0 | Sep 19, 2025 | clinicaltrials |
| NCT07169903 | Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT(STAR012) | not yet recruiting | Phase 3 | 587 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07162883 | Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 3 | 122 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07106528 | Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 128 | Peking Union Medical College HospitalOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT06970782 | Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure(KYLIN-3) | not yet recruiting | Phase 3 | 278 | Avistone Biotechnology Co., Ltd.INDUSTRY | 0 | May 21, 2025 | clinicaltrials |
| NCT06961201 | Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase | not yet recruiting | Phase 3 | 94 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT06955325 | Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations(UPLIFT) | not yet recruiting | Phase 3 | 270 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT01394679 | A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer | not yet recruiting | Phase 3 | 154 | Cell>Point LLCINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06858410 | Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma | not yet recruiting | Phase 3 | 36 | Guangdong Association of Clinical TrialsOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT06847334 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 772 | Shanghai Henlius BiotechINDUSTRY | 0 | Feb 26, 2025 | clinicaltrials |
| NCT06828757 | Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 94 | Hunan Province Tumor HospitalOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06789796 | a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. | not yet recruiting | Phase 3 | 636 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 11, 2025 | clinicaltrials |
| NCT06704620 | Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 430 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06719336 | Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) | not yet recruiting | Phase 3 | 182 | Anhui Shi, MDOTHER | 0 | Dec 5, 2024 | clinicaltrials |
| NCT06672133 | Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC(RALLY) | not yet recruiting | Phase 3 | 524 | Jinming YuOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06581380 | JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 394 | JenKem Technology Co., Ltd.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT06526624 | A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 406 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Jul 30, 2024 | clinicaltrials |
| NCT06441344 | Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell(SCLC) | not yet recruiting | Phase 3 | 136 | Taizhou HospitalOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06380348 | JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations | not yet recruiting | Phase 3 | 398 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Apr 23, 2024 | clinicaltrials |
| NCT06335355 | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | not yet recruiting | Phase 2 / Phase 3 | 401 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06323148 | Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) | not yet recruiting | Phase 3 | 226 | Fudan UniversityOTHER | 0 | Mar 21, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials